Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 trial evaluates the safety and potential benefit of lifileucel, a tumor-infiltrating lymphocyte therapy, in adults with previously treated advanced soft tissue sarcoma including undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Tumor samples are taken to generate lifileucel, followed by a conditioning regimen and a lifileucel infusion, with up to four days of interleukin-2 support. Participants are monitored with visits every six weeks for six months, then every three months for up to five years. The study aims to determine whether this autologous cell therapy can produce meaningful anti-tumor activity in this difficult-to-treat cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 16 years of age at the time of signing the informed consent and assent.
* Participants who are \> 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
* Participant must have a confirmed diagnosis of histologically confirmed unresectable or metastatic UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen.
* Participant has demonstrated progressive disease on or after the last line of therapy.
* Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation.
* Following tumor resection for lifileucel generation, the participant will have at least one measurable lesion, as defined by RECIST v1.1 at Baseline.
* Participant is expected to achieve washout from investigational or anticancer therapy(ies).
* If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection.
* Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per NCI-CTCAE), except for peripheral neuropathy, alopecia, or vitiligo.
* Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
* Participants must have adequate organ function.
* Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

Exclusion Criteria:

* Participant has symptomatic untreated brain metastases.
* The participant has an ECOG performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated life expectancy of\< 6 months.
* Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation.
* Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease \[SCID\] or AIDS).
* Participant has a history of hypersensitivity to any component of the study intervention.
* Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated \> 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence.

Other protocol defined inclusion/exclusion criteria could apply.

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: Iovance Biotherapeutics Study Team
• Email: Clinical.Inquiries@iovance.com
• Phone: 844-845-4682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

  This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07432932

• Dose‑escalated, short‑course proton radiation for inoperable soft tissue sarcoma

  This will try higher-dose, shorter-course proton radiation to see if it controls tumors better in adults with inoperable soft tissue sarcoma.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT07173972

• Investigating OKN4395 and Pembrolizumab for Solid Tumors

  This study is testing a new drug called OKN4395, alone and with another drug called pembrolizumab, to see if it can help people with solid tumors who have run out of other treatment options.

  Recruiting at 10 sites Phase 1 Epkin · Beverly Hills, California and 9 other locations · NCT06789172

• Strasbourg pST soft tissue sarcoma care patterns and survival

  This study looks back at how closely soft tissue sarcoma care in Strasbourg followed international guidelines and whether that related to overall survival, comparing patient care from 2010-2016 to 2017-2024.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07864870

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.